Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Novo Nordisk's SWOT analysis: stock outlook amid GLP-1 market growth
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...
Money Morning2h
3 Pharma Stocks Getting Fat Off GLP-1: Here's the Best Buy Now
Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...
eLife17h
Phosphoglycerate mutase regulates Treg differentiation through control of serine synthesis and one-carbon metabolism
The results highlight an important physiological function of PGAM in the differentiation and suppressive activity of Treg cells by regulating serine synthesis. This role is proposed to intersect with ...
Daily9h
FDA approves Semaglutide for renal protection among diabetes patients with CKD
Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...
yr.no17h
Novo Machado
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...